about
Cardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population.Renal denervation for the management of resistant hypertensionTuberculous Constrictive PericarditisPirouetting Away the Pain With Music.Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction.Atrial Fibrillation in the Young: A Neurologist's NightmareOne heart, two cardiomyopathiesT1 at 1.5T and 3T compared with conventional T2* at 1.5T for cardiac siderosis.The Tpeak - Tend interval as an electrocardiographic risk marker of arrhythmic and mortality outcomes: A systematic review and meta-analysis.Educational Case: A 57-year-old man with chest pain.Magnetic resonance imaging phantoms for quality-control of myocardial T1 and ECV mapping: specific formulation, long-term stability and variation with heart rate and temperatureMechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance.Markers of left ventricular decompensation in aortic stenosis.Towards accurate and precise T 1 and extracellular volume mapping in the myocardium: a guide to current pitfalls and their solutions.Device-identified atrial fibrillation at pacing clinics. Should it guide anticoagulation?The role of myocardial fibrosis in determining the success rate of ablation for the treatment of atrial fibrillation.Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance.Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial.Clinical value of cardiovascular magnetic resonance in patients with MR-conditional pacemakers.NOAC or Warfarin for Atrial Fibrillation: Does Time in Therapeutic Range Matter?Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome.Students of the past...doctors of the future.Pokémon Go: cardiovascular benefit or injury risk?How sweet is the pacemaker?An unexpected cause of hypertrophic myocardiumKounis syndrome: not to be sneezed at.Role of simvastatin as an immunomodulator in type 2 diabetes: response to Lopes-Virella et al.An unusual but reversible cause of ventricular fibrillation.Combined salmeterol and fluticasone for COPD.The association between ECV and microcirculation perfusion abnormalities in non-ischemic dilated cardiomyopathy.Wave intensity analysis and assessment of myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy.Systolic T1 mapping for estimation of myocardial diffuse fibrosis.Histological validation of a new CMR T1-mapping-based protocol to improve accuracy for fibrosis assessment in patients with aortic stenosis.Improved coronary magnetic resonance angiography using gadobenate dimeglumine in pediatric congenital heart disease.Percutaneous coronary intervention in the elderly: are drug coated balloons the future?Hypertrophic Cardiomyopathy-Past, Present and Future.Assisted dying - should the UK change its stance?Rheumatoid arthritis: mapping the future.Iatrogenic myocarditis-biomarkers, cardiovascular MRI and the need for early diagnosis.Challenging Occam's Razor: An Unusual Combination of Sarcoidosis and Amyloidosis. The Value of Cardiac Magnetic Resonance Imaging in Infiltrative Cardiomyopathies.
P50
Q26767019-B181A192-713C-4C3F-A221-BCA1007B0AC3Q26775639-453E8B58-048A-4EE4-97B8-1E144AA88918Q27301320-688B8996-6251-4459-9B8E-50AE8B33FB57Q30377070-51742107-587E-4AE6-B154-41FF73AD3FF3Q33727302-10D6F2E5-7AF9-4057-85FE-EEC8D66CC9A7Q35438395-4902FEC0-F4A3-48CA-A0E0-BBFB4666C7A2Q35974883-24F2C06C-C177-4400-A660-80A3EFF64923Q36318293-BA5053B6-2E55-4CA5-A7B2-4ABE6728AF06Q36383747-1C0F1189-CDE8-437D-B071-38B595E60AF0Q36798068-357D90B0-DAFB-434F-8FF1-A5ECCABA15D1Q37278487-577C1B92-1815-4AEC-AA06-29FB3F574E86Q37318366-8054F686-D949-49EC-BC2F-D372790DA4D5Q38215381-F824C601-F31E-41A0-AEB3-7F175370E55CQ38671622-F760CD39-74B3-4E4A-9E9E-828BFBCCDCE2Q38716575-98BF77A0-DA14-4936-BABB-BFA82CEE4563Q39168889-7E8CE7E2-3C1B-4169-A9E1-CAB9F0273127Q39555199-5F21AED8-A8EC-463A-9A62-387AE087871EQ39909400-C98416A2-9801-438D-B7BF-4A06A38B5FCAQ40296177-2637A118-EC85-4642-BB4E-9EDE82BBCE76Q40544229-9090CB9E-A0C6-4B10-B63C-9C3091A887C2Q40650085-AF1018EC-CF09-4F28-9FFD-B82505B25888Q40653218-34A0D1EC-C5EA-4011-92CF-88BD298238B9Q41654127-D1232685-B553-4357-B431-21B7D6A50A22Q41700185-82B0641B-C535-445A-9B74-5C8E8A0B4F36Q41916293-A88234CE-069C-4B17-B845-1D21C5167C9EQ44675969-D4C65592-D5EB-468B-9BC1-425FC392D933Q44995626-52A0AE1D-85BB-4AD1-B08C-434720CD5ED5Q45421332-E2735D57-9578-4155-83E2-9674DE7F9F1AQ45899355-93D8E98D-0B5D-457B-903D-CDA745517A6CQ46130179-41028BBF-8E57-42DA-866C-35E21596C0D3Q46419451-E3CAA417-F623-4ECF-B805-D8E384C59766Q47131324-AF90A43B-D61A-4B6A-A3E3-993A02AD0454Q47131362-F5DDFD11-C3C8-430C-BBC5-F453CAE1CEBCQ47655523-07000580-2910-40FF-82D1-1058E5EBDBE9Q47763813-221BB2EE-B8F4-424F-8B00-762DCE6BE06FQ47787101-E4251CA4-5BF7-4CC7-8789-AD9430C28030Q48127257-23BBAE17-3C4B-4DDC-A7C7-CAED510F2016Q48492825-4D00C1B2-89DA-432F-BAE1-5D6BDF77AC18Q49331322-022BC494-50AE-4DCE-B220-21F1D838E618Q50223983-E2197241-BC10-4C73-9B6D-4831D09EC79F
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Vassilios Vassiliou
@ast
Vassilios Vassiliou
@en
Vassilios Vassiliou
@es
Vassilios Vassiliou
@nl
type
label
Vassilios Vassiliou
@ast
Vassilios Vassiliou
@en
Vassilios Vassiliou
@es
Vassilios Vassiliou
@nl
altLabel
Vassilis Vassiliou
@en
prefLabel
Vassilios Vassiliou
@ast
Vassilios Vassiliou
@en
Vassilios Vassiliou
@es
Vassilios Vassiliou
@nl
P106
P1153
35595915300
P31
P496
0000-0002-4005-7752